Danaher reported strong Q3 results with revenue up 8.3% to $6.55 billion and adjusted EPS of $2.11, surpassing analyst estimates. Growth was driven by the Biotechnology and Diagnostics segments despite challenges from changing respiratory test demand and pricing pressures in China. UBS reiterated its Buy rating, highlighting Danaher's raised 2026 earnings outlook, while some analysts remain cautious due to valuation concerns. The company’s strong performance and optimistic outlook support continued investor interest in the healthcare diagnostics sector.
Following UBS's reaffirmation of a Buy rating on Danaher after its strong Q3 results, the stock shows mixed signals on Pluang as of Oct 22, 2026 23:31 WIB. Danaher (DHR) trades at USD 231.51, down 1.10% for the day, with a market cap of $164.40 billion. Despite the slight daily dip, investor sentiment on Pluang remains positive with 88% of order activity on the buy side and a typical hold time of 69 days.
Danaher Corporation reported strong Q3 earnings with revenue up 8.3% year-over-year to $6.55 billion and adjusted EPS of $2.11, driven by growth in its Diagnostics segment. However, challenges remain from volatile respiratory revenue and pricing pres...
Danaher Corporation reported Q3 results showing an 8.3% year-over-year revenue increase, primarily driven by acquisitions and tariff refunds rather than organic growth. The company achieved an adjusted operating margin of 29%, surpassing guidance, bu...
Danaher reported Q3 2026 earnings per share of $2.11, surpassing analyst estimates of $1.92, although revenue slightly missed expectations at $6.55 billion versus $6.56 billion forecast. The company highlighted improving customer demand and faster co...
Danaher Corporation reported strong Q3 2026 results with net earnings rising 34.5% year-over-year to $1.2 billion, or $1.71 per diluted share. Revenues increased 8.5% to $6.6 billion, driven by core growth excluding respiratory revenue. The company r...
